It has also been observed that cetuximab-mediated EGFR blockade downregulates interferon-gamma (IFN-γ)-induced programmed death ligand 1 (PD-L1) expression in HNSCC; this may signify the restoration of the antitumor immune response [6, 7]. Here, EGFR is linked to head and neck squamous cell carcinoma.